Patent Grant
7943683
The present invention generally relates to polymeric compositions that can be processed into films using continuous processes to produce products having substantially uniform physical properties, including physical and thermo-mechanical integrity. The compositions include polymers or copolymers comprising 4-hydroxybutyrate, and can be processed into films that are tough, have high strength and low modulus.
Poly-4-hydroxybutyrate (P4HB) and copolymers thereof can be produced using transgenic fermentation methods, see, for example, U.S. Pat. No. 6,548,569 to Williams et al., and are produced commercially, for example, by Tepha, Inc. (Cambridge, Mass.). Poly-4-hydroxybutyrate (P4HB, TephaFLEX® biomaterial) is a strong, pliable thermoplastic polyester that, despite its biosynthetic route, has a relatively simple structure
The polymer belongs to a larger class of materials called polyhydroxyalkanoates (PHAs) that are produced by numerous microorganisms (see, for example,: Steinbüchel A., et al. Diversity of Bacterial Polyhydroxyalkanoic Acids, FEMS Microbial. Lett. 128:219-228 (1995)). In nature these polyesters are produced as storage granules inside cells, and serve to regulate energy metabolism. They are also of commercial interest because of their thermoplastic properties, and relative ease of production. Several biosynthetic routes are currently known to produce P4HB:
This schematic shows some of the known biosynthetic pathways for the production of P4HB. Pathway enzymes are: 1. Succinic semialdehyde dehydrogenase, 2. 4-hydroxybutyrate dehydrogenase, 3. diol oxidoreductase, 4. aldehyde dehydrogenase, 5. Coenzyme A transferase and 6. PHA synthetase.
Chemical synthesis of P4HB has been attempted, but it has been impossible to produce the polymer with a sufficiently high molecular weight that is necessary for most applications (Hori, Y., et al., Polymer 36:4703-4705 (1995)).
U.S. Pat. Nos. 6,245,537, 6,623,748 and 7,244,442 describe methods of making PHAs with little to no endotoxin, which is suitable for medical applications. U.S. Pat. Nos. 6,548,569, 6,838,493, 6,867,247, 7,268,205, and 7,179,883 describe use of PHAs to make medical devices. Copolymers of P4HB include 4-hydroxybutyrate copolymerized with 3-hydroxybutyrate or glycolic acid (U.S. patent application No. 20030211131 by Martin and Skraly, U.S. Pat. No. 6,316,262 to Huisman et al., and U.S. Pat. No. 6,323,010 to Skraly et al.). Methods to control molecular weight of PHA polymers have been disclosed by U.S. Pat. No. 5,811,272 to Snell et al.
PHAs with controlled degradation and degradation in vivo of less than one year are disclosed by U.S. Pat. Nos. 6,548,569, 6,610,764, 6,828,357, 6,867,248, and 6,878,758 to Williams et al. and WO 99/32536 to Martin et al. Applications of P4HB have been reviewed in Williams, S. F., et al., Polyesters, III, 4:91-127 (2002), and by Martin, D. et al. Medical Applications of Poly-4-hydroxybutyrate: A Strong Flexible Absorbable Biomaterial, Biochem. Eng. J. 16:97-105 (2003). Medical devices and applications of P4HB have also been disclosed by WO 00/56376 to Williams et al.
Several patents including U.S. Pat. Nos. 6,555,123, 6,585,994, and 7,025,980 describe the use of PHAs in tissue repair and engineering.
In the practice of surgery there currently exists a need for absorbable films with improved performance. These films can be used, for example, to reinforce tissue structures. They may also be used as anti-adhesion membranes, or as components of other devices. A number of other absorbable materials have been used to produce films for use in surgery. For example, films have been made from polylactic acid (PLA) or copolymers containing the different stereoisomers of lactic acid or glycolic acid. SurgiWrap™, for example, is a medical film implant made from a copolymer of L-lactide and D,L-lactide, 70:30. These materials do not, however, have ideal properties for many procedures and applications. Films made from PLA, like SurgiWrap™, have high modulus values, making them stiff, and preventing these films from contouring to bodily tissues when implanted. The high modulus values of PLA [see Gruber and O'Brien, 2002, in Biopolymers: Polyesters, III (Doi, Y. and Steinbüchel, A., Eds.) vol. 4, pp. 235-250. Weinheim: Wiley-VCH.] result in films of low toughness, and these properties, combined with other PLA properties, limit the ability of the polymer scientist to process PLA into thin films with good handling properties, for example, by solvent casting and melt extrusion.
U.S. Pat. No. 6,548,569 to Williams et al. discloses an unoriented film of poly-4-hydroxybutyrate produced by compression molding in a batch process, not a continuous process. The film had a tensile strength of 5.27 kgf/mm2 (7,500 psi), tensile modulus of 6.6 kgf/mm2 (9,400 psi), and elongation at break of 1,000%.
It is an object of the present invention to provide methods to produce films of absorbable polymers that have relatively low modulus values, and which are tough and have high strength.
It is a further object of the present invention to provide continuous processes to produce such films, such as melt processing and solvent casting, as compared to batch processes such as compression molding.
It is another object of the present invention to provide films which can be used in medical applications, for example, as implants such as devices for anti-adhesion barriers, tissue separation and temporary tissue support, coatings on medical devices, including stent coatings, as well as devices for tissue in-growth particularly where the film has been rendered porous.
It is therefore an object of the invention to provide continuous processes for polymer film production which yield materials with excellent physical and mechanical properties, and the resulting polymer films.
Continuous processing methods for making absorbable polymeric films with one or more of the following properties: high toughness, low modulus, high tensile strength, and thickness less than 10 mm, more preferably less than 1 mm, and more preferably less than 100 μm, have been developed. In the preferred embodiment, the polymer is a polyhydroxyalkanoate, and in the most preferred embodiment, the polymer comprises 4-hydroxybutyrate. A particularly preferred embodiment is a film of poly-4-hydroxybutyrate or copolymer thereof, wherein the film has a tensile strength greater than 5.5 kgf/mm2, tensile modulus less than 181 kgf/mm2, and elongation at break from 10-500%, wherein the film is derived by a continuous process such as melt extrusion or solvent casting, followed by orientation to more than 25% of the film's original length in one or more directions.
These can be used for a variety of purposes including fabrication of medical devices.
“Poly-4-hydroxybutyrate” as generally used herein means a homopolymer comprising 4-hydroxybutyrate units. It may be referred to herein as P4HB or TephaFLEX® biomaterial (manufactured by Tepha, Inc., Cambridge, Mass.).
“Copolymers of poly-4-hydroxybutyrate” as generally used herein means any polymer comprising 4-hydroxybutyrate with one or more different hydroxy acid units.
“Blend” as generally used herein means a physical combination of different polymers, as opposed to a copolymer comprised of two or more different monomers.
Orientation is the process by which the film is stretched beyond its yield point and plastically deformed, but does not break (i.e. it retains mechanical and physical integrity). The degree of orientation may be expressed as the percentage or ratio that the film is stretch when compared to the original film prior to orientation. Films are preferably oriented by stretching the film by at least 25% of the film's original length in one or more directions.
“Tensile modulus” is the ratio of stress to strain for a given material within its proportional limit. As used herein, low tensile modulus means a material having a tensile modulus less than 180 kgf/mm2.
“Tensile strength” is the maximum or ultimate tensile load per unit area of original cross section area of the test specimen, within the gauge boundaries, sustained by the specimen during the test. As used herein, high tensile strength means a material test sample having a tensile strength of at least 5.3 kgf/mm2.
“Toughness” means a property of a material by virtue of which it can absorb energy; the actual work per unit volume or unit mass of material that is required to rupture it. Toughness is usually proportional to the area under the load-elongation curve such as the tensile stress-strain curve. (Rosato's Plastics Encyclopedia and Dictionary, Oxford Univ. Press, 1993.) As used herein, high toughness means a value greater than 10 kgf/mm2.
“Elongation” or extensibility of a material means the amount of increase in length resulting from, as an example, the tension to break a specimen. It is expressed usually as a percentage of the original length. (Rosato's Plastics Encyclopedia and Dictionary, Oxford Univ. Press, 1993.)
“Molecular weight” as used herein, unless otherwise specified, refers to the weight average molecular weight (Mw), not number average molecular weight (Mn).
“Absorbable” as generally used herein means the material is broken down in the body and eventually eliminated from the body within five years.
“Biocompatible” as generally used herein means the biological response to the material or device being appropriate for the device's intended application in vivo. Any metabolites of these materials should also be biocompatible.
I. Composition
Methods have been developed to produce films of P4HB and copolymers with exceptional toughness. These methods may be used to prepare films that have substantially uniform physical properties and physical integrity. The methods may be run continuously, which is particularly advantageous in manufacturing. These films can be prepared by solution casting or by melt extrusion followed by orientation.
A. Polymers
The processes described herein can typically be used with any of the polyhydroxyalkanoate polymers, including blends and copolymers thereof.
In a preferred embodiment, the polymer is poly-4-hydroxybutyrate (P4HB) or a copolymer thereof. Copolymers include P4HB with 3-hydroxybutyrate, and P4HB with glycolic acid monomer. P4HB and copolymers thereof can be obtained from Tepha, Inc. of Cambridge, Mass.
B. Films
In a preferred embodiment, films can be prepared with thickness of less than 10 mm, more preferably less than 1 mm, and even more preferably less than 100 μm. It has been discovered that very thin films of P4HB polymer or copolymers thereof can be prepared with substantially uniform physical properties, and physical integrity, by solution casting. Using this method, films cast from solutions of the polymer or copolymers dissolved in organic solvents can have thicknesses that are less than 100 μm, and even less than 50 μm. For example, solution cast films of P4HB have been prepared with thicknesses of 20 to 50 μm. With appropriate choice of solvent, polymer and casting conditions, thinner films of P4HB can be produced, or the cast films can be stretched and oriented uniaxially or biaxially to yield thinner and stronger films than the unoriented cast films.
It has also been discovered that very thin films of P4HB and copolymer thereof can be prepared with exceptional toughness and strength. These cast films have a tensile strength of approximately 7.2 kgf/mm2 and elongation to break of approximately 200%. In comparison, a commercially available implantable film of PLA (SurgiWrap™ Bioresorbable Film) has a tensile strength of approximately 5.9 kgf/mm2 and an elongation to break of 95%.
Films of P4HB polymer or copolymers thereof, with exceptional toughness, can be prepared by melt processing followed by orientation (stretching). For example, a film of P4HB may be prepared by melt extrusion followed by stretching. Stretching substantially increases stress as measured in kgf/mm2. For example, the stress in an unoriented P4HB film prepared by melt extrusion, thickness of 0.022 mm and width of 13 mm was measured on a MTS mechanical analyzer to be 4.98 kgf/mm2. The stress in the same P4HB film after stretching the sample 3.6× the original length to a thickness of 0.010 mm and width of 8 mm was measured to be 14.13 kgf/mm2 with an elongation to break of the oriented (or stretched) sample of approximately 25%.
Comparative ball burst testing can be done by ASTM D6797-02, [Standard Test Method for Bursting Strength of Fabrics Constant-Rate-of-Extension (CRE) Ball Burst Test (1 cm ball, 1.6 cm opening)]. This testing shows that P4HB films are stronger and tougher than SurgiWrap™ film, another commercially available, absorbable film used as an implant material. Ball burst strength and elongation for a 40 μm P4HB film were 5.6 kgf and 39 mm (ball displacement at break), respectively, while for SurgiWrap they were 3.2 kgf and 3.4 mm (ball displacement at break), respectively, for a slightly thicker film (50 μm). The higher breaking force and longer extension to break for the P4HB film demonstrate its greater strength and toughness.
In a preferred embodiment, the films described herein have toughness greater than 10 kgf/mm2, more preferably greater than 50 kgf/mm2, and even more preferably greater than 100 kgf/mm2.
In a preferred embodiment, the films described herein preferably have tensile strength greater than 5.5 kgf/mm2, more preferably greater than 7.0 kgf/mm2, and even more preferably greater than 10.0 kgf/mm2.
In a preferred embodiment, the films described herein preferably have an elongation to break greater than 10%, more preferably greater than 15%, and even more preferably greater than 20%.
C. Other Components
The P4HB polymer and copolymer films may contain other materials, including plasticizers, nucleants, other polymers, additives, and compatibilizers. Examples of plasticizers are disclosed by U.S. Pat. No. 6,905,987 to Noda et al. Other components may be added to impart benefits such as, but not limited to, increased stability, including oxidative stability, brightness, color, flexibility, resiliency, workability, processibility (by addition of processing aids), viscosity modifiers, and odor control.
Active components, including therapeutic, diagnostic and/or prophylactic agents, such as drugs, or other substances may be incorporated. Such compositions may be used for controlled release of the drugs or other substances. These may be proteins, peptides, sugars, polysaccharides, glycoproteins, lipids, lipoproteins, nucleic acid molecules, or combinations thereof. Moreover, the films may comprise proteins, polysaccharides, peptides, as well as other substances including allograft and xenograft materials. It may be advantageous to incorporate contrast agents, radiopaque markers, or radioactive substances.
For certain applications it may also be desirable to incorporate fillers, including materials such as titanium dioxide, calcium carbonate, hydroxyapatite, and tricalcium phosphate. Such fillers may include agents that can subsequently be leached or washed out of the film to render it porous.
D. Formation Into Devices
Films made from P4HB polymers and copolymers thereof by solvent casting and melt extrusion are characterized by their thinness, which may be less than 100 μm, and even less than 50 μm. These films are also characterized by high tensile strength and toughness and high ductility prior to orientation. These films have properties that are substantially improved for medical application relative to PLA-based films.
The films possess properties that are desirable in preparing medical products, particularly implantable medical devices. For example, the films may be used to make partially or fully absorbable biocompatible medical devices, or components thereof. Such devices include, but are not limited to: stent, stent graft, stent coating, drug delivery device, device for temporary wound or tissue support, repair patch, tissue engineering scaffold, retention membrane (for example, to retain bone graft), anti-adhesion membrane, tissue separation membrane, hernia repair device, device coating (including devices to improve fixation), cardiovascular patch, catheter balloon, vascular closure device, sling, biocompatible coating, rotator cuff repair device, meniscus repair device, adhesion barrier, guided tissue repair/regeneration device, articular cartilage repair device, nerve guide, tendon repair device, intracardiac septal defect repair device, including but not limited to atrial septal defect repair devices and PFO closure devices, left atrial appendage (LAA) closure device, pericardial patch, bulking and filling agent, vein valve, heart valve, bone marrow scaffold, meniscus regeneration device, ligament and tendon graft, ocular cell implant, spinal fusion device, imaging device, skin substitute, dural substitute, bone graft substitute, wound dressing, and hemostat.
II. Methods of Manufacturing Films
A. Method of Making P4HB Polymer or Copolymer Films by Solvent Casting
In a preferred method, a film of P4HB polymer or copolymer thereof may be prepared by solution casting as follows. A homogeneous solution of P4HB in a suitable solvent such as 1,4-dioxane or tetrahydrofuran (THF) is prepared at approximately 10-15 wt/vol %. The solution should have a viscosity of approximately 400 to 7,400 cP. The polymer solution is pumped at approximately room temperature through a 150 mm slot die with a 400 μm die gap onto a moving web, for example, of aluminum foil. The web speed is approximately 0.5 m/min and traveled 5 m before being collected on a collection roller. The speed is adjusted to ensure evaporation of the solvent. One or more separate air drying zones set at 50-60° C. were employed to remove solvent from the polymer film before collection on the final roll. A number of parameters can be varied to control the film thickness including, but not limited to, the pump speed, the die gap and width, the polymer concentration and the web speed.
B. Method of Making P4HB Polymer or Copolymer Films by Melt Processing Through Melt Extrusion
Films can also be prepared by melt-extrusion methods. Preferred methods are a T-die extrusion method or an inflation method.
In the formation of the film by melt-extrusion, the barrel and T-die temperatures for preferably carrying out the formation are 80 to 250° C., more preferably 100 to 210° C. The melting of the P4HB is insufficient at temperature less than 100° C. When the temperature is higher than 250° C., the P4HB markedly undergoes thermal decomposition. However, the site of the barrel directly below a hopper may have a temperature of less than 100° C. The molten film exits the T-die and is cast over a chilled moving surface preferably, one or more rotating cylindrical cast rollers with surface temperature maintained at 5-100° C., but more preferably at 10° C. This step is followed by a take-up step to wind up the extruded film. Film thickness can be varied by changing the gap of the T-die slit, polymer flow rate, and cast roll speed.
In the formation of film by the inflation method, an inflation molding circular die is used instead of a T-die to extrude cylindrical film of P4HB. The molten cylindrical film is cooled and solidified by blowing it up with cold air blown from the central portion of the circular die, and the cylindrical film which had been blown up is collected with a take-up machine. Film thickness can be varied by changing the gap of the inflation die slit, polymer flow rate, cooling air pressure and temperature and take-up speed.
C. Orientation of Films
The melt-extrusion films and solvent cast films show improved mechanical properties when stretched. The melt-extrusion film may be stretched by several methods such as a roll stretching and/or a stretching method using a tenter frame. The melt-extrusion film can be stretched at a temperature between room temperature and 150° C. at a stretch ratio of 0.25 to 15. To increase the processing rate, the stretching may be more preferably carried out at a temperature in the range of from 40 to 80° C. The stretching may be monoaxial stretching for forming a monoaxially oriented film, consecutive biaxial stretching for forming a biaxially oriented film and simultaneous biaxial stretching for forming a plane-oriented film. When the melt-extrusion film is stretched, the tensile strength at break in the direction in which the film is stretched is increased.
The present invention will be further understood by referenced to the following non-limiting examples.
A homogeneous solution of P4HB in 1,4-dioxane (15% wt/vol) was prepared by dissolving 91 g of P4HB in 610 ml of 1,4-dioxane. This solution had a viscosity of approximately 7,400 cP. The polymer solution was pumped at approximately 36 ml/min at room temperature through a 150 mm slot die with a 400 μm die gap onto a moving web of aluminum foil. The web speed was approximately 0.5 m/min and traveled 5 m before being collected on a collection roller. Three separate air drying zones set at 50-60° C. were employed to desolventize the polymer film before collection on the final roll. Using these conditions, a 43 μm thick film was obtained. A thinner film (24 μm thick) was obtained by increasing the web speed to 0.75 m/min and reducing the polymer concentration to 10%. Thinner films may also be obtained by reducing the die gap or pump speed. Mechanical properties of the solvent cast films compared to commercially available SurgiWrap™ 70:30 Poly (L-lactide-co-D,L-lactide) are shown in Tables 1 and 2.
P4HB (Tepha, Inc., Cambridge, Mass.) (Mw 506,000) was ground into small pieces using a Fritsch cutting mill (Pulversette 15, 10 mm bottom sieve) and dried under vacuum overnight to less than 0.01% (w/w) water. Dried pellets of the polymer were fed into an extruder barrel of a Leistritz 27 mm, 40:1 L/D co-rotating twin screw extruder fitted with 10 inch wide coat-hanger die with adjustable die lips initially set at 0.015 inch gap. Eleven heating zones of the extruder were set at 75, 90, 110, 110, 130, 130, 130, 150, 150, 200 and 200° C. and the die temperature was set at 200° C. Polymer feed rate was set at 1 lb/hr and the extruder speed was set at 100 rpm. Melt pressure measured 247 psi and melt temperature measured 208° C. A 7-inch diameter roll was used for casting. Roll surface temperature was kept at 12° C. and film line speed was maintained at 3 feet per minute. The properties of a film derived by this process before and after biaxial orientation is shown in Table 3.
Tables 4 and Table 5 below illustrate the advantageous mechanical properties of P4HB films prepared by the methods described herein. Their tensile properties are compared with films made from an absorbable polymer, L-PLA (L-polylactic acid), unoriented P4HB films produced in this work and with unoriented P4HB films produced in a batch process.
This application claims priority under 35 U.S.C. 119 to U.S. Ser. No. 60/868,182 filed Dec. 1, 2006, “Medical Devices Containing Oriented Films of Poly-4-Hydroxybutyrate and Copolymers” Said Rizk, David P. Martin, Kicherl Ho and Simon F. Williams.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3598122 | Zaffaroni et al. | Aug 1971 | A |
| 3598123 | Zaffaroni et al. | Aug 1971 | A |
| 3731683 | Zaffaroni | May 1973 | A |
| 3797494 | Zaffaroni | Mar 1974 | A |
| 3982543 | Schmitt et al. | Sep 1976 | A |
| 4031894 | Urquhart et al. | Jun 1977 | A |
| 4201211 | Chandrasekaran et al. | May 1980 | A |
| 4205399 | Jamiolkowski | Jun 1980 | A |
| 4286592 | Chandrasekaran | Sep 1981 | A |
| 4314557 | Chandrasekaran | Feb 1982 | A |
| 4379454 | Campbell et al. | Apr 1983 | A |
| 4435180 | Leeper | Mar 1984 | A |
| 4537738 | Holmes | Aug 1985 | A |
| 4559222 | Enscore et al. | Dec 1985 | A |
| 4573995 | Chen et al. | Mar 1986 | A |
| 4588580 | Gale et al. | May 1986 | A |
| 4603070 | Steel et al. | Jul 1986 | A |
| 4645502 | Gale et al. | Feb 1987 | A |
| 4648978 | Makinen et al. | Mar 1987 | A |
| 4664655 | Orentreich et al. | May 1987 | A |
| 4704282 | Campbell et al. | Nov 1987 | A |
| 4711241 | Lehmann | Dec 1987 | A |
| 4758234 | Orentreich et al. | Jul 1988 | A |
| 4788062 | Gale et al. | Nov 1988 | A |
| 4792336 | Hlavacek et al. | Dec 1988 | A |
| 4816258 | Nedberge et al. | Mar 1989 | A |
| 4826493 | Martini | May 1989 | A |
| 4849226 | Gale | Jul 1989 | A |
| 4853226 | Machida et al. | Aug 1989 | A |
| 4856188 | Sibalis | Aug 1989 | A |
| 4876331 | Doi | Oct 1989 | A |
| 4880592 | Martini et al. | Nov 1989 | A |
| 4908027 | Enscore et al. | Mar 1990 | A |
| 4910145 | Holmes et al. | Mar 1990 | A |
| 4938763 | Dunn et al. | Jul 1990 | A |
| 4943435 | Baker et al. | Jul 1990 | A |
| 5002067 | Berthelsen et al. | Mar 1991 | A |
| 5026381 | Li | Jun 1991 | A |
| 5032638 | Wang et al. | Jul 1991 | A |
| 5041100 | Rowland et al. | Aug 1991 | A |
| 5085629 | Goldberg et al. | Feb 1992 | A |
| 5124371 | Tokiwa et al. | Jun 1992 | A |
| 5128144 | Korsatko-Wabnegg | Jul 1992 | A |
| 5171308 | Gallagher et al. | Dec 1992 | A |
| 5204382 | Wallace et al. | Apr 1993 | A |
| 5236431 | Gogolewski et al. | Aug 1993 | A |
| 5245023 | Peoples et al. | Sep 1993 | A |
| 5250430 | Peoples et al. | Oct 1993 | A |
| 5271961 | Mathiowitz et al. | Dec 1993 | A |
| 5278201 | Dunn et al. | Jan 1994 | A |
| 5278202 | Dunn et al. | Jan 1994 | A |
| 5278256 | Bellis | Jan 1994 | A |
| 5292860 | Shiotani et al. | Mar 1994 | A |
| 5306286 | Stack et al. | Apr 1994 | A |
| 5334698 | Witholt et al. | Aug 1994 | A |
| 5386004 | Obuchi et al. | Jan 1995 | A |
| 5443458 | Eury | Aug 1995 | A |
| 5468253 | Bezwada et al. | Nov 1995 | A |
| 5480394 | Ishikawa | Jan 1996 | A |
| 5480794 | Peoples et al. | Jan 1996 | A |
| 5489470 | Noda | Feb 1996 | A |
| 5502116 | Noda | Mar 1996 | A |
| 5502158 | Sinclair et al. | Mar 1996 | A |
| 5512669 | Peoples et al. | Apr 1996 | A |
| 5516565 | Matsumoto | May 1996 | A |
| 5516883 | Hori et al. | May 1996 | A |
| 5534432 | Peoples et al. | Jul 1996 | A |
| 5536564 | Noda | Jul 1996 | A |
| 5550173 | Hammond et al. | Aug 1996 | A |
| 5551954 | Buscemi et al. | Sep 1996 | A |
| 5563239 | Hubbs et al. | Oct 1996 | A |
| 5584885 | Seckel | Dec 1996 | A |
| 5614576 | Rutherford et al. | Mar 1997 | A |
| 5625030 | Williams et al. | Apr 1997 | A |
| 5629077 | Turnlund et al. | May 1997 | A |
| 5635215 | Boschetti et al. | Jun 1997 | A |
| 5646217 | Hammond | Jul 1997 | A |
| 5648100 | Boschetti et al. | Jul 1997 | A |
| 5670161 | Healy et al. | Sep 1997 | A |
| 5703160 | Dehennau et al. | Dec 1997 | A |
| 5705187 | Unger | Jan 1998 | A |
| 5709854 | Griffith-Cima et al. | Jan 1998 | A |
| 5711933 | Bichon et al. | Jan 1998 | A |
| 5728752 | Scopelianos et al. | Mar 1998 | A |
| 5735863 | Della Valle et al. | Apr 1998 | A |
| 5753364 | Rutherford et al. | May 1998 | A |
| 5753708 | Koehler et al. | May 1998 | A |
| 5789536 | Liggat et al. | Aug 1998 | A |
| 5811272 | Snell | Sep 1998 | A |
| 5814071 | McDevitt et al. | Sep 1998 | A |
| 5814599 | Mitragotri et al. | Sep 1998 | A |
| 5824333 | Scopelianos et al. | Oct 1998 | A |
| 5824751 | Hori et al. | Oct 1998 | A |
| 5834582 | Sinclair et al. | Nov 1998 | A |
| 5840331 | Van Cauter et al. | Nov 1998 | A |
| 5842477 | Naughton et al. | Dec 1998 | A |
| 5855619 | Caplan et al. | Jan 1999 | A |
| 5874040 | Liggat et al. | Feb 1999 | A |
| 5876452 | Athanasiou et al. | Mar 1999 | A |
| 5876455 | Harwin | Mar 1999 | A |
| 5879322 | Lattin et al. | Mar 1999 | A |
| 5917002 | Doi et al. | Jun 1999 | A |
| 5919478 | Landrau et al. | Jul 1999 | A |
| 5935506 | Schmitz et al. | Aug 1999 | A |
| 5990162 | Scharf | Nov 1999 | A |
| 5994478 | Asrar et al. | Nov 1999 | A |
| 6056970 | Greenawalt et al. | May 2000 | A |
| 6119567 | Schindler et al. | Sep 2000 | A |
| 6214387 | Berde et al. | Apr 2001 | B1 |
| 6245537 | Williams | Jun 2001 | B1 |
| 6316262 | Huisman | Nov 2001 | B1 |
| 6323010 | Skraly | Nov 2001 | B1 |
| 6454811 | Sherwood et al. | Sep 2002 | B1 |
| 6514515 | Williams | Feb 2003 | B1 |
| 6548569 | Williams | Apr 2003 | B1 |
| 6555123 | Williams | Apr 2003 | B2 |
| 6585994 | Williams | Jul 2003 | B2 |
| 6600010 | Mao et al. | Jul 2003 | B2 |
| 6610764 | Martin | Aug 2003 | B1 |
| 6623748 | Clokie | Sep 2003 | B2 |
| 6656489 | Mahmood et al. | Dec 2003 | B1 |
| 6680046 | Boschetti | Jan 2004 | B1 |
| 6770356 | O'Donnell et al. | Aug 2004 | B2 |
| 6828357 | Martin | Dec 2004 | B1 |
| 6838493 | Williams | Jan 2005 | B2 |
| 6867247 | Williams | Mar 2005 | B2 |
| 6867248 | Martin | Mar 2005 | B1 |
| 6878248 | Signer et al. | Apr 2005 | B2 |
| 6878758 | Williams | Apr 2005 | B2 |
| 6905987 | Noda | Jun 2005 | B2 |
| 7025980 | Williams | Apr 2006 | B1 |
| 7179883 | Williams | Feb 2007 | B2 |
| 7244442 | Williams | Jul 2007 | B2 |
| 7268205 | Williams | Sep 2007 | B2 |
| 7553923 | Williams et al. | Jun 2009 | B2 |
| 20020028243 | Masters | Mar 2002 | A1 |
| 20020156150 | Williams et al. | Oct 2002 | A1 |
| 20020173558 | Williams et al. | Nov 2002 | A1 |
| 20030091803 | Bond et al. | May 2003 | A1 |
| 20031018589 | Buiser et al. | Oct 2003 | |
| 20030211131 | Martin | Nov 2003 | A1 |
| 20040220355 | Whitehouse | Nov 2004 | A1 |
| 20040234576 | Martin et al. | Nov 2004 | A1 |
| 20050025809 | Hasirci et al. | Feb 2005 | A1 |
| 20050107505 | Shinoda et al. | May 2005 | A1 |
| 20050137678 | Varma | Jun 2005 | A1 |
| 20050267516 | Soleimani | Dec 2005 | A1 |
| 20060058470 | Rizk | Mar 2006 | A1 |
| 20060177513 | Martin et al. | Aug 2006 | A1 |
| 20060287659 | Terenghi et al. | Dec 2006 | A1 |
| 20070010851 | Chanduszko et al. | Jan 2007 | A1 |
| 20080051490 | Williams et al. | Feb 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| 2307637 | May 1999 | CA |
| 2259098 | Jul 1999 | CA |
| 2298421 | Feb 2000 | CA |
| 39 37 649 | May 1991 | DE |
| 0 258 781 | Mar 1988 | EP |
| 0 344 704 | Dec 1989 | EP |
| 0 349 505 | Mar 1990 | EP |
| 0 423 484 | Apr 1991 | EP |
| 0 429 403 | May 1991 | EP |
| 0 432 443 | Jun 1991 | EP |
| 0 452 111 | Oct 1991 | EP |
| 0 507 554 | Oct 1992 | EP |
| 0 601 885 | Jun 1994 | EP |
| 0 628 586 | Dec 1994 | EP |
| 0 754 467 | Jan 1997 | EP |
| 1130043 | Sep 2001 | EP |
| 1266984 | Dec 2002 | EP |
| 2166354 | May 1986 | GB |
| 62-209144 | Sep 1987 | JP |
| 03-187386 | Aug 1991 | JP |
| 04-292619 | Oct 1992 | JP |
| 04-326932 | Nov 1992 | JP |
| 5-023189 | Feb 1993 | JP |
| 5-194141 | Nov 1993 | JP |
| 06-264306 | Sep 1994 | JP |
| 06-336523 | Dec 1994 | JP |
| 07-275344 | Oct 1995 | JP |
| 08-089264 | Apr 1996 | JP |
| 09-098793 | Apr 1997 | JP |
| 09-507091 | Jul 1997 | JP |
| WO 9218164 | Oct 1992 | WO |
| WO 9305824 | Apr 1993 | WO |
| WO 9320134 | Oct 1993 | WO |
| WO 9402184 | Feb 1994 | WO |
| WO 9406886 | Mar 1994 | WO |
| WO 9503356 | Feb 1995 | WO |
| WO 9517216 | Jun 1995 | WO |
| WO 9520614 | Aug 1995 | WO |
| WO 9520615 | Aug 1995 | WO |
| WO 9520621 | Aug 1995 | WO |
| WO 9523250 | Aug 1995 | WO |
| WO 9533874 | Dec 1995 | WO |
| WO 9600263 | Jan 1996 | WO |
| WO 9608535 | Mar 1996 | WO |
| WO 9618420 | Jun 1996 | WO |
| WO 9621427 | Jul 1996 | WO |
| WO 9640304 | Dec 1996 | WO |
| WO 9704036 | Feb 1997 | WO |
| WO 9707153 | Feb 1997 | WO |
| WO 9715681 | May 1997 | WO |
| WO 9730042 | Aug 1997 | WO |
| WO 9804292 | Feb 1998 | WO |
| WO 9839453 | Sep 1998 | WO |
| WO 9848028 | Oct 1998 | WO |
| WO 9851812 | Nov 1998 | WO |
| WO 9911196 | Mar 1999 | WO |
| WO 9914313 | Mar 1999 | WO |
| WO 9932536 | Jul 1999 | WO |
| WO 9935192 | Jul 1999 | WO |
| WO 0051662 | Sep 2000 | WO |
| WO 0056376 | Sep 2000 | WO |
| WO 0110421 | Feb 2001 | WO |
| WO 0115671 | Mar 2001 | WO |
| WO 0119361 | Mar 2001 | WO |
| WO 2004101002 | Nov 2004 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20080132602 A1 | Jun 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60868182 | Dec 2006 | US |
